Advertisement

AASLD Liver Meeting | Conference

Dr. Jordi Bruix on Efficacy and Safety of Regorafenib in HCC After Sorafenib

November 17th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.

Dr. Ghassan Abou-Alfa on Impact of Second-Line Regorafenib in HCC

November 17th 2016

​Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.

Tumor Burden Limits Liver Transplant Feasibility for HCC

November 17th 2016

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

Multidisciplinary Care Associated With Improved OS for HCC Patients

November 15th 2016

Multidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival for patients with early-stage hepatocellular carcinoma.

Dr. Montano-Loza on Link Between HCC Risk and High Visceral Adipose Tissue

November 15th 2016

Aldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.

DAAs Not Associated With Increased HCC Risk in HCV Patients

November 15th 2016

Treatment with direct-acting antiviral therapy did not increase the risk of developing hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection.

Researchers Validate Novel Prediction Index for HCC After Liver Transplant

November 15th 2016

A new system for gauging the probability for hepatocellular carcinoma recurrence following liver transplant surgery has proved successful.

Dr. Naveed Zafar Janjua on Impact of Hepatitis C Treatment Timing on HCC Risk

November 15th 2016

Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).

Regorafenib Renews Hope in Hepatocellular Carcinoma

November 14th 2016

There has been renewed optimism in hepatocellular carcinoma with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA.

Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC

November 14th 2016

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

Percutaneous and Laparoscopic RFA Outcomes Similar for HCC

November 14th 2016

Similar recurrence-free survival was demonstrated with radiofrequency ablation using percutaneous and laparoscopic methods for patients with hepatocellular carcinoma who were eligible for ablation.

Dr. Tim F. Greten on Immunotherapy in HCC

November 14th 2016

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute (NCI), discusses the potential for immunotherapy in hepatocellular carcinoma (HCC).

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

November 13th 2016

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Biomarkers Define Future Age of Immunotherapy in Cancer

November 13th 2016

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients

November 13th 2016

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients

November 13th 2016

​George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).

ERK Inhibition May Explain Regorafenib Success in Sorafenib-Resistant HCC

November 13th 2016

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.

Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant

November 13th 2016

Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.

Advertisement
Advertisement